NTRK fusions are an actionable molecular target that occur in ~1.0% of all cancers, although this varies greatly across specific tumour types. Where an NTRK fusion is identified, it can be treated with a TRK inhibitor - regardless of the tumour histology or prior treatment lines. But how can we identify such rare mutations?

To help guide clinicians in implementing routine NTRK screening, the ESMO Translational Research and Precision Medicine Working Group have developed a consensus statement on suitable testing approaches, including a simple algorithm.

Join lead author Professor Caterina Marchiò and our chair, Professor Dr Marc Peeters, for an in-depth discussion of TRK fusion cancer.

If you would like to receive CME credits for watching this video please visit Oncology Knowledge into Practice.

If you scroll down the page you will see a button asking you to complete a short evaluation and claim credit.

If you would like to register for free to receive similar education please visit www.onkip.com.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

If you are from the Germany, Spain or Italy and want to listen to advice from experts from your country please visit Oncology knowledge into practice.